- Home
- FVR vs INBX Comparison
FVR vs INBX Comparison
Compare FVR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVR
- INBX
- Stock Information
- Founded
- FVR 2016
- INBX 2010
- Country
- FVR United States
- INBX United States
- Employees
- FVR N/A
- INBX N/A
- Industry
- FVR
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- FVR
- INBX Health Care
- Exchange
- FVR NYSE
- INBX Nasdaq
- Market Cap
- FVR 282.6M
- INBX 237.5M
- IPO Year
- FVR 2024
- INBX 2020
- Fundamental
- Price
- FVR $18.63
- INBX $16.17
- Analyst Decision
- FVR
- INBX Hold
- Analyst Count
- FVR 0
- INBX 1
- Target Price
- FVR N/A
- INBX N/A
- AVG Volume (30 Days)
- FVR 861.6K
- INBX 104.7K
- Earning Date
- FVR 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- FVR N/A
- INBX N/A
- EPS Growth
- FVR N/A
- INBX N/A
- EPS
- FVR N/A
- INBX 118.83
- Revenue
- FVR $55,737,152.00
- INBX $1,687,000.00
- Revenue This Year
- FVR N/A
- INBX N/A
- Revenue Next Year
- FVR N/A
- INBX N/A
- P/E Ratio
- FVR N/A
- INBX $0.14
- Revenue Growth
- FVR N/A
- INBX 24.26
- 52 Week Low
- FVR $18.25
- INBX $10.80
- 52 Week High
- FVR $19.50
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- FVR N/A
- INBX 58.46
- Support Level
- FVR N/A
- INBX $15.46
- Resistance Level
- FVR N/A
- INBX $16.20
- Average True Range (ATR)
- FVR 0.00
- INBX 0.60
- MACD
- FVR 0.00
- INBX 0.01
- Stochastic Oscillator
- FVR 0.00
- INBX 63.78
About FVR FRONTVIEW REIT INC
FrontView REIT Inc is an internally managed net-lease REIT that is experienced in acquiring, owning, and managing out parcel properties that are net-leased to a diversified group of tenants. Its tenants include service-oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services as well as general retail tenants.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.